H R Black
Affiliation: Rush University Medical Center
- Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trialHenry R Black
Rush Medical College of Rush University, Chicago, IL 60612, USA
JAMA 289:2073-82. 2003..Hypertensive patients are often given a calcium antagonist to reduce cardiovascular disease risk, but the benefit compared with other drug classes is controversial...
- The burden of cardiovascular disease: following the link from hypertension to myocardial infarction and heart failureHenry R Black
Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, 1700 West Van Buren, Suite 470, Chicago, IL 60612, USA
Am J Hypertens 16:4S-6S. 2003..Aggressive lowering of BP is critical to help reduce the risk of CVD and help prevent the development of HF...
- Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical regionHenry R Black
Department of Preventive Medicine, Rush University Medical Center, Chicago, Illinois 60612, USA
J Hypertens 23:1099-106. 2005..To examine regional differences in the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial...
- One-year study of felodipine or placebo for stage 1 isolated systolic hypertensionH R Black
Department of Preventive Medicine, Rush Medical College of Rush University at Rush Presbyterian Saint Luke s Medical Center, Chicago, Illinois, USA
Hypertension 38:1118-23. 2001..Larger and longer studies will be needed to document any long-term reduction in cardiovascular event rates associated with treating stage 1 systolic hypertension...
- Isolated systolic hypertension in the elderly: lessons from clinical trials and future directionsH R Black
Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Chicago IL 60612, USA
J Hypertens Suppl 17:S49-54. 1999..We must also encourage the development of antihypertensive drugs that lower SBP more effectively than those that are currently available...
- Will better-tolerated antihypertensive agents improve blood pressure control? JNC VI revisitedH R Black
Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
Am J Hypertens 12:225S-230S. 1999....
- Controlled-release doxazosin as combination therapy in hypertension: the GATES studyHenry R Black
Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
J Clin Hypertens (Greenwich) 8:159-66; quiz 167-8. 2006..0%), the frequency of adverse events was similar for doxazosin GITS and placebo. Doxazosin GITS was effective as combination antihypertensive therapy with the major classes of antihypertensive agents...
- Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trialGeorge L Bakris
Hypertensive Diseases Unit, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
Lancet 375:1173-81. 2010..We assessed the effects of these drug combinations on progression of chronic kidney disease...
- The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled studyH R Black
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA
Am J Hypertens 13:468-74. 2000..These findings demonstrate that doxazosin add-on therapy is an effective, well-tolerated treatment strategy for patients with inadequately controlled hypertension...
- Optimal blood pressure: how low should we go?H R Black
Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Rush Medical College of Rush University, Chicago, Illinois 60612, USA
Am J Hypertens 12:113S-120S. 1999..Setting appropriate blood pressure goals and working to meet them through aggressive antihypertensive treatment, with multiple agents if necessary, can reduce those risks...
- Calcium channel blockers in the treatment of hypertension and prevention of cardiovascular disease: results from major clinical trialsHenry R Black
Department of Preventive Medicine, Rush University Medical Center, Chicago, Illinois 60612, USA
Clin Cornerstone 6:53-66. 2004....
- Doxazosin as combination therapy for patients with stage 1 and stage 2 hypertensionHenry R Black
Rush Presbyterian St Luke s Medical Center, 1700 W Van Buren St, Suite 470, Chicago, IL 60612 3824, USA
J Cardiovasc Pharmacol 41:866-9. 2003..The positive effects of doxazosin on serum lipids make combination therapy with doxazosin an attractive treatment option for patients who have concomitant hyperlipidemia or glucose intolerance...
- Exercise capacity and the risk of death in women: the St James Women Take Heart ProjectMartha Gulati
Department of Preventive Medicine, Rush Heart Institute, Rush Presbyterian St Luke s Medical Center, 1725 West Harrison Ave, Suite 020, Chicago, Ill 60612, USA
Circulation 108:1554-9. 2003..The hypothesis that reduced exercise capacity is associated with an increased risk of death was investigated in a cohort of 5721 asymptomatic women who underwent baseline examinations in 1992...
- A comparison of two sphygmomanometers that may replace the traditional mercury column in the healthcare workplaceWilliam J Elliott
Department of Preventive Medicine, Rush Medical College, Chicago, IL 60612, USA
Blood Press Monit 12:23-8. 2007....
- Management of older hypertensive patients: is there a difference in approach?Henry R Black
Rush University Medical Center, Chicago, IL 60612, USA
J Clin Hypertens (Greenwich) 5:11-6. 2003..No older person should suffer a preventable, life-threatening event or become confined to a wheel chair if attention to lifestyle issues and a few pills a day could avoid that outcome...
- PrehypertensionWilliam J Elliott
Department of Preventive Medicine, Rush Medical College, Rush University Medical Center, Chicago, IL 60612, USA
Nat Clin Pract Cardiovasc Med 4:538-48. 2007..In this Review, we attempt to summarize the recently published data concerning the epidemiology, attendant risks and potential treatment options for this important and growing public-health problem...
- Graded blood pressure reduction in hypertensive outpatients associated with use of a device to assist with slow breathingWilliam J Elliot
Department of Preventive Medicine, Rush Medical College of Rush University, Rush University Medical Center, Chicago, IL 60612, USA
J Clin Hypertens (Greenwich) 6:553-9; quiz 560-1. 2004..Thus, even without training, hypertensive patients who receive a device to guide slow breathing significantly lowered their office SBP if the total time spent in slow breathing over 8 weeks exceeded a "threshold" value of 180 minutes...
- Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical dataHenry R Black
Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
Am Heart J 147:564-72. 2004..This article reviews the role of the RAAS in the development of hypertension and discusses the rationale for the use of eplerenone with other medications affecting the RAAS to control blood pressure...
- Treatment of hypertension in the elderlyWarren J Elliott
Department of Preventive Medicine, RUSH Medical College of RUSH University at RUSH Presbyterian St Luke s Medical Center, 1700 West Van Buren Street, Chicago, IL 60612, USA
Am J Geriatr Cardiol 11:11-20; quiz 20-2. 2002..Future cardiovascular risk may be related directly to the blood pressure attained, rather than to how it was attained...
- Risk stratification of older patientsHenry R Black
Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
Am J Hypertens 15:77S-81S. 2002..Otherwise, a multidrug regimen is constructed and additional agents added in logical fashion. A majority of patients with higher risk can attain control at the specified BP goal safely and effectively by using a combination of agents...
- ASH position paper: treatment of hypertension in patients with diabetes-an updateGeorge L Bakris
Hypertensive Diseases and Diabetes Center, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
J Clin Hypertens (Greenwich) 10:707-13; discussion 714-5. 2008..Last, an updated algorithm is provided that incorporates many of the new findings and is suggested as a starting point to achieve blood pressure goals...
- The coronary artery disease paradoxH R Black
Rush-Presbyterian-St. Luke's Medical Center, Rush Medical College, Chicago, Illinois, USA
Am J Hypertens 9:2S-10S. 1996..This paper will review these possible reasons for the coronary artery disease paradox, concentrating on classification and problems with drug therapy...
- Goal-oriented hypertension management: translating clinical trials to practiceGregory M Singer
Rush University Hypertension Service, Rush Presbyterian St Luke s Medical Center, Chicago, Ill 60612, USA
Hypertension 40:464-9. 2002..Although DBP control was easy to achieve, achieving SBP goal still remained difficult. Employing goal-oriented management can translate BP control results achieved in clinical trials into outpatient practice...
- Prognostic value of the duke treadmill score in asymptomatic womenMartha Gulati
Department of Preventive Medicine, Rush University Medical Center, Chicago, Illinois, USA
Am J Cardiol 96:369-75. 2005..The role of ST-segment changes and symptoms with stress testing in asymptomatic women does not provide additional prognostic information...
- The prognostic value of a nomogram for exercise capacity in womenMartha Gulati
Department of Preventive Medicine, Rush University Medical Center, Chicago, USA
N Engl J Med 353:468-75. 2005..Our objectives were to construct a nomogram to permit determination of predicted exercise capacity for age in women and to assess the predictive value of the nomogram with respect to survival...
- Expanding the definition of hypertension to incorporate global cardiovascular riskNitin Khosla
Rush University Hypertension Center, Rush Presbyterian St Luke s Medical Center, 1700 W Van Buren Street, Suite 470, Chicago, IL 60612, USA
Curr Hypertens Rep 8:384-90. 2006..To change this alarming trend, physicians must become aggressive in using the available armamentarium of lifestyle modifications and drugs in treating hypertension and other risk factors that increase the burden of atherosclerosis...
- Hypertension in women: the Women Take Heart projectA lice A Furumoto-Dawson
Department of Preventive Medicine, Rush Medical College, Rush Presbyterian St Lukes Medical Center, Chicago, IL 60612, USA
J Clin Hypertens (Greenwich) 5:38-46. 2003..1% of self-reported hypertensives. Results from this study and national surveys indicate that hypertension detection and control remain major public health challenges in preventing cardiovascular disease in older women...
- Resistant hypertension revisited: a comparison of two university-based cohortsJay P Garg
Department of Preventive Medicine, Rush University Medical Center, Chicago, Illinois, 60612, USA
Am J Hypertens 18:619-26. 2005..To assess whether the reasons for and treatment of RH have changed, we determined the frequency of various causes of resistance, the proportion of patients achieving goal BP, and the changes made in antihypertensive regimens...
- Number needed to treat: solid science or a path to pernicious rationing?H R Black
Rush Presbyterian St Luke s Medical Center, Rush Medical College, Chicago, Illinois, USA
Am J Hypertens 11:128S-134S; discussion 135S-137S. 1998..We need to be sure that future trials of chronic conditions such as hypertension are done with this trial paradigm, so that those who pay for care have the accurate knowledge needed to spend their money wisely...
- Antihypertensive therapy and cardiovascular disease. Impact of effective therapy on disease progressionH R Black
Department of Preventive Medicine, Rush-Presbyterian-St Luke's Medical Center, Chicago, IL 60612-3824, USA
Am J Hypertens 11:3S-8S. 1998..This article reviews the impact of antihypertensive treatment on cardiovascular disease and treatment endpoints...
- Achieving blood pressure goals globally: five core actions for health-care professionals. A worldwide call to actionG Bakris
Department of Medicine, Hypertensive Diseases Center, University of Chicago, Pritzker School of Medicine, Chicago, IL 60637, USA
J Hum Hypertens 22:63-70. 2008..These actions should be pursued with vigour in accordance with current clinical guidelines, with the details of implementation adapted to the economic and cultural setting...
- The paradigm has shifted to systolic blood pressureH R Black
Department of Preventive Medicine, Rush University Medical Center, Chicago, IL 60612, USA
J Hum Hypertens 18:S3-7. 2004....
- Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trialGeorge L Bakris
University of Chicago, Department of Medicine, Hypertensive Disease Unit, Chicago, Ill, USA
Hypertension 56:824-30. 2010..The results of this trial highlight the importance of ambulatory BP monitoring in the design of hypertension clinical studies...
- Heart rate response to exercise stress testing in asymptomatic women: the st. James women take heart projectMartha Gulati
Department of Medicine Cardiology and Preventive Medicine, Northwestern University, Chicago, Ill 60611, USA
Circulation 122:130-7. 2010..We investigated the association between HR response to exercise testing and age with prognosis in 5437 asymptomatic women...
- Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart ProjectMartha Gulati
Department of Medicine and Preventive Medicine, Northwestern University, 201 E Huron, Chicago, IL 60611, USA
Arch Intern Med 169:843-50. 2009..Women with clinical findings suggestive of ischemia but without findings of obstructive coronary artery disease (CAD) on angiography represent a frequent clinical problem; predicting prognosis is challenging...
- Improving blood pressure control rates: is there more we can do?George L Bakris
Hypertension Center, Endocrine Division, The University of Chicago School of Medicine, Chicago, IL, USA
J Clin Hypertens (Greenwich) 9:134-42. 2007
- Guidelines for hypertension: are quality-assurance measures on target?Gregory M Singer
Rush University Hypertension Service, Chicago, Ill, USA
Hypertension 43:198-202. 2004..Goal-oriented strategy, especially in diabetic subjects, should be aggressively sought rather than relaxing goals to promote achievement...
- Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatmentMichael L Maitland
Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA
Clin Cancer Res 15:6250-7. 2009..This prospective, single-center, cohort study characterized ambulatory blood pressure monitoring as an early pharmacodynamic biomarker of VEGF signaling pathway inhibition by sorafenib...
- Prehypertension and cardiovascular disease risk in the Women's Health InitiativeJudith Hsia
Department of Medicine, George Washington University, 2150 Pennsylvania Ave NW, Washington, DC 20037, USA
Circulation 115:855-60. 2007..Prehypertension is common and is associated with increased vascular mortality. The extent to which it increases risk of nonfatal myocardial infarction, stroke, and congestive heart failure is less clear...
- Pharmacologic considerations in the positioning of beta-blockers in antihypertensive therapyDomenic A Sica
Clinical Pharmacology and Hypertension, Virginia Commonwealth University Health System, Richmond, VA 23298, USA
Curr Hypertens Rep 10:330-5. 2008..The most recently introduced drugs, the vasodilating beta-blockers carvedilol and nebivolol, are now being broadly evaluated as to their efficacy and tolerability in clinical practice...
- The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosisPaula T Einhorn
National Heart, Lung, and Blood Institute, Division of Epidemiology and Clinical Applications, Bethesda, MD 20892 7936, USA
Am Heart J 153:42-53. 2007..However, questions have been raised regarding the validity of the HF diagnosis...
- Prehypertension--what is it and should it be treated?Marvin Moser
J Clin Hypertens (Greenwich) 8:812-8. 2006
- Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Henry R Black
New York University School of Medicine, New York, New York, USA
Diabetes Care 31:353-60. 2008..Optimal initial antihypertensive drug therapy in people with the metabolic syndrome is unknown...
- Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trialDeepak L Bhatt
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
J Am Coll Cardiol 49:1982-8. 2007..The purpose of this study was to determine the possible benefit of dual antiplatelet therapy in patients with prior myocardial infarction (MI), ischemic stroke, or symptomatic peripheral arterial disease (PAD)...
- Microalbuminuria, chronic renal disease, and the effects of the metabolic syndrome on cardiovascular eventsMarvin Moser
J Clin Hypertens (Greenwich) 9:551-6. 2007..The authors maintained full control of the discussion and the resulting content of this article; Novartis had no input in the choice of topic, speakers, or content...
- The editor's roundtable: revisiting the role of beta blockers in hypertensionWilliam C Roberts
Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas, USA
Am J Cardiol 100:253-67. 2007
- The role of therapeutic inertia and the use of fixed-dose combination therapy in the management of hypertensionJan Basile
Ralph H Johnson VA Medical Center, Charleston, SC, USA
J Clin Hypertens (Greenwich) 9:636-45. 2007
- Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Jackson T Wright
Department of Medicine, General Clinical Research Center, Cleveland, Ohio, USA
Arch Intern Med 168:207-17. 2008....
- The cardiometabolic syndrome and calcium channel blocker combination drugsJames R Sowers
Diabetes Research Center, University of Missouri Columbia, Columbia, MO, USA
J Cardiometab Syndr 2:207-12. 2007..The authors maintained full control of the discussion and the resulting content of this article...
- Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging studyHenry R Black
New York University School of Medicine, New York, NY 10016, USA
J Clin Hypertens (Greenwich) 9:760-9. 2007....
- Effect of calcium and vitamin D supplementation on blood pressure: the Women's Health Initiative Randomized TrialKaren L Margolis
HealthPartners Research Foundation, Box 1524, Mailstop 21111R, Minneapolis, Minnesota 55440 1524, USA
Hypertension 52:847-55. 2008..01 (95% CI: 0.96 to 1.06.) In postmenopausal women, calcium plus vitamin D3 supplementation did not reduce either blood pressure or the risk of developing hypertension over 7 years of follow-up...
- Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Linda B Piller
University of Texas Health Science Center at Houston, School of Public Health, Houston, TX 77030, USA
J Clin Hypertens (Greenwich) 8:649-56; quiz 657-8. 2006..One patient died following an angioedema episode. The occurrence of angioedema in the angiotensin-converting enzyme inhibitor arm corresponds with previously reported angioedema-angiotensin-converting enzyme inhibitor associations...
- Chronotherapeutic oral drug absorption system verapamil is effective in reducing morning blood pressure in African Americans: a post hoc analysis of the chrono trialL Michael Prisant
Medical College of Georgia, Augusta, GA, USA
J Natl Med Assoc 97:377-83. 2005..In a trial conducted in actual clinical practices, the CODAS formulation of verapamil was shown to be safe and effective in African Americans, Caucasians, Hispanics and Asians...
- Treatment of elderly hypertensive patients with a delayed-release verapamil formulation in a community-based trialMichael A Weber
State University of New York Downstate College of Medicine, Brooklyn, NY 11203, USA
Am J Geriatr Cardiol 13:131-6. 2004..CODAS verapamil was found to be efficacious and well tolerated among elderly hypertensive patients in this community trial...
- Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trialJohn B Kostis
Department of Medicine, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, One Robert Wood Johnson Place, PO Box 19, New Brunswick, NJ 08903 0019, USA
Am J Hypertens 17:103-11. 2004..We compared the efficacy and safety of omapatrilat to a representative angiotensin-converting enzyme (ACE) inhibitor, enalapril...
- Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureAram V Chobanian
Boston University School of Medicine, Boston, Mass, USA
Hypertension 42:1206-52. 2003..Positive experiences, trust in the clinician, and empathy improve patient motivation and satisfaction. This report serves as a guide, and the committee continues to recognize that the responsible physician's judgment remains paramount...
- Estrogen plus progestin and the risk of coronary heart diseaseJoAnn E Manson
Division of Preventive Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02215, USA
N Engl J Med 349:523-34. 2003..In this report, we provide the final results with regard to estrogen plus progestin and CHD from the Women's Health Initiative (WHI)...
- The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 reportAram V Chobanian
Department of Medicine, Boston University School of Medicine, Boston, Mass, USA
JAMA 289:2560-72. 2003..Empathy builds trust and is a potent motivator. Finally, in presenting these guidelines, the committee recognizes that the responsible physician's judgment remains paramount...
- Angioedema in heart failure: occurrence with ACE inhibitors and safety of angiotensin receptor blocker therapyDomenic A Sica
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
Congest Heart Fail 8:334-41, 345. 2002..The need to reduce renin-angiotensin aldosterone system activity in a heart failure patient would seem to justify the small risk of angioedema with ARB therapy in a patient having previously experienced ACE inhibitor-related angioedema...
- Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)William C Cushman
J Clin Hypertens (Greenwich) 4:393-404. 2002..Achievable control rates in varied practice settings and geographic regions and factors that predict improved blood pressure control are not well identified...
- Chrono: a community-based hypertension trial of a chronotherapeutic formulation of verapamilL Michael Prisant
Hypertension and Clinical Pharmacology, Medical College of Georgia, Augusta, GA 30912 3105, USA
Am J Ther 9:476-83. 2002..Upward titration of Verelan PM from 200 to 400 mg nearly doubled the DBP response rate (45.8% to 85.3%). This chronotherapeutic formulation of verapamil was well tolerated in this community trial...
- Current concepts of pharmacotherapy in hypertension: ACE inhibitor-related angioedema: can angiotensin-receptor blockers be safely used?Domenic A Sica
Department of Medicine, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
J Clin Hypertens (Greenwich) 4:375-80. 2002..Such justification might include the presence of heart failure or proteinuric nephropathic states among other considerations...
- Design of the Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trialJohn B Kostis
University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick 08903 0019, USA
Am J Hypertens 15:193-8. 2002..Additional analyses will be conducted in men and women, in diabetic patients, in different risk classes and according to prior evidence of vascular disease...
- A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trialDeepak L Bhatt
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Am Heart J 150:401. 2005..We sought to characterize the risk factors and treatments of a diverse contemporary population of patients with atherothrombosis...
- Expanding the definition and classification of hypertensionThomas D Giles
Louisiana State University School of Medicine, New Orleans, LA 70112, USA
J Clin Hypertens (Greenwich) 7:505-12. 2005..We believe it would be preferable to classify all individuals as either normal or hypertensive, based on their cardiovascular evaluation, using the four categories of normal and stages 1, 2, and 3 hypertension...
- ACE inhibitors: over two decades of useDomenic A Sica
Virginia Commonwealth University, Richmond, VA, USA
J Clin Hypertens (Greenwich) 7:531-7. 2005..Dr. Henry R. Black of Rush University Medical Center, Chicago, IL; and Dr. Vito M. Campese of the University of Southern California, Los Angeles, CA...
- Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trialFrans H H Leenen
University of Ottawa Heart Institute, Ottawa, Ontario, Canada
Hypertension 48:374-84. 2006..Some, but not all, of these differences may be explained by less effective blood pressure control in the lisinopril arm...
- Blood pressure reduction is not the only determinant of outcomePeter S Sever
International Centre for Circulatory Health, Imperial College London, 59 N Wharf Rd, London, W2 1PG, UK
Circulation 113:2754-72; discussion 2773-4. 2006
- Feasibility of treating prehypertension with an angiotensin-receptor blockerStevo Julius
University of Michigan, Department of Internal Medicine, Division of Cardiovascular Medicine, Ann Arbor, MI 48106, USA
N Engl J Med 354:1685-97. 2006..Prehypertension is considered a precursor of stage 1 hypertension and a predictor of excessive cardiovascular risk. We investigated whether pharmacologic treatment of prehypertension prevents or postpones stage 1 hypertension...
- Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic eventsDeepak L Bhatt
Cleveland Clinic, Cleveland, USA
N Engl J Med 354:1706-17. 2006..Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events...
- Calcium plus vitamin D supplementation and the risk of fracturesRebecca D Jackson
Division of Endocrinology, Ohio State University, 485 McCampbell, 1581 Dodd Dr, Columbus, OH 43210, USA
N Engl J Med 354:669-83. 2006..The efficacy of calcium with vitamin D supplementation for preventing hip and other fractures in healthy postmenopausal women remains equivocal...
- Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification TrialBarbara V Howard
MedStar Research Institute Howard University, Washington, DC, USA
JAMA 295:655-66. 2006..Multiple epidemiologic studies and some trials have linked diet with cardiovascular disease (CVD) prevention, but long-term intervention data are needed...
- Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification TrialShirley A A Beresford
Department of Epidemiology, University of Washington, Seattle, WA 98195 7236, USA
JAMA 295:643-54. 2006..Observational studies and polyp recurrence trials are not conclusive regarding the effects of a low-fat dietary pattern on risk of colorectal cancer, necessitating a primary prevention trial...
- Commentary on ICEBERGHenry R Black
New York University School of Medicine, New York, NY 10003, USA
J Clin Hypertens (Greenwich) 9:557. 2007
- The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directionsVictor J Dzau
Duke University Medical Center and Health System DUMC 3701, Durham, NC 27710, USA
Circulation 114:2871-91. 2006
- The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease)Victor J Dzau
Duke University Medical Center and Health System DUMC 3701, Durham, NC 27710, USA
Circulation 114:2850-70. 2006
- Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification TrialRoss L Prentice
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Wash 98109, USA
JAMA 295:629-42. 2006..The hypothesis that a low-fat dietary pattern can reduce breast cancer risk has existed for decades but has never been tested in a controlled intervention trial...
- Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and PreventiClive Rosendorff
Veterans Health Administration, USA
Circulation 115:2761-88. 2007
- MASTERS OF SCIENCE IN CLINICAL RESEARCHHenry Black; Fiscal Year: 2004..Their success will be followed yearly by the Program Director of the Clinical Research Curriculum Award ..
- Web-Based Project Tracking to Enhance IRB OperationsHenry Black; Fiscal Year: 2003..abstract_text> ..